SPECIALLY COLLECTED PAPERS
Shimadzu Review 80[3・4] (2023)
Abstract
Shimadzu Diagnostics Corporation launched the RAISUS to market in 2001, followed by the RAISUS ANY in 2010 and the RAISUS S4 in 2016, with each model used by clinical microbiology laboratories to identify bacterial species and perform antimicrobial susceptibility testing. At medical institutions, clinical microbiology laboratories isolate microorganisms in specimens taken from patients with suspected infections, identify the microorganisms, and perform antimicrobial susceptibility testing. This testing saves patient lives and also maintains a wide range of effective treat-ment options against microbial infection. Accurate antimicrobial susceptibility testing allows physicians to select the right therapeutic option for the patient, while the correct identification of drug-resistant bacteria curbs the unnecessary use of antimicrobials. The proper use of antimicrobials prevents the emergence of drug-resistant bacteria and maintains a wide range of effective antimicrobial treatment options. This article describes the basic principles of the RAISUS S4 and presents examples of its use in clinical settings.
1Product Development Department, Shimadzu Diagnostics Corporation, Ibaraki, Japan
2Business Plan Promotion Office, Shimadzu Diagnostics Corporation, Tokyo, Japan
*The information contained in Shimadzu Review has not been modified since the original publication date. Please be aware that in some cases, products mentioned within the articles are no longer available.